Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyJohns Hopkins Health Plans CGT Model Coverage Upda…
    Ask Trek AI about this page
    Currentjohns_hopkins_health_plansPolicy CMS24.26

    Cell and Gene Therapy Access Model - PPMCO

    Customize your policy alerts

    Sign up for johns_hopkins_health_plans Policy CMS24.26 alerts

    Get alerted when Policy CMS24.26 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs prior authorization, clinical criteria, authorized treatment centers, and coverage processes for CASGEVY and LYFGENIA under the Maryland Cell and Gene Therapy Access Model as applied by Johns Hopkins Health Plans (Priority Partners Managed Care Organization). Affects members with sickle cell disease seeking these gene therapies and providers/ATCs administering them.

    Policy Summary
    PayerJohns Hopkins Health Plans
    PolicyCell and Gene Therapy Access Model - PPMCO
    Policy CodePolicy CMS24.26
    Change TypeAdded authorized treatment center
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with a letter of medical necessity and supporting clinical documentation demonstrating MDH clinical criteria; requests will be reviewed by plan Medical Directors.
    SourceLink
    POLICY UPDATE CHANGES

    University of Maryland Medical Center (UMMC) was added as an approved treatment center for CASGEVY effective 01/26/2026.

    2authorized treatment centers currently listed in region
    12 monthsminimum authorization validity period
    >=2 VOCs/yearCASGEVY eligibility: recurrent VOCs threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >=4 VOEs/24 monthsLYFGENIA eligibility: VOE frequency threshold
    Ages >=12minimum age for both CASGEVY and LYFGENIA

    Coverage Criteria for CGT Model Therapies

    MDH clinical criteria for CGT Model therapies

    Covered when ALL of the following are met (per MDH clinical criteria as adopted by PPMCO):

    General model eligibility: Member has a diagnosis of sickle cell disease and is enrolled under the Maryland CGT Model; therapy will be administered at an Authorized Treatment Center (ATC)

    ATC must be contracted or a single case agreement established if out-of-network

    Age and prescriber: Patient is 12 years of age or older at expected time of gene therapy administration and therapy is prescribed by or in collaboration with a Board Certified Hematologist with SCD expertise>=12 years
    Therapy-specific clinical criteria - CASGEVY: For CASGEVY (exagamglogene autotemcel, J3392): documentation of sickle cell disease with recurrent vaso-occlusive crises (defined as >= 2 documented VOCs per year in the previous 24 months based on provider attestation); examples include acute pain events requiring facility visit and parenteral pain meds or RBC transfusion, acute chest syndrome, priapism >2 hours requiring facility visit, or splenic sequestration; confirmatory genetic testing; prior use or intolerance of hydroxyurea at any point; clinically fit and stable for transplantation (documented evaluation required); prescriber must confirm FDA label parameters, screening and monitoringsee node text

    CASGEVY indication for transfusion-dependent beta-thalassemia (TDT) is excluded from the CGT Model

    Therapy-specific clinical criteria - LYFGENIA: For LYFGENIA (lovotibeglogene autotemcel, J3394): experienced >=4 VOEs in the previous 24 months OR currently receiving chronic transfusion therapy for recurrent VOEs; VOE examples include acute pain events requiring facility visit and parenteral pain meds or RBC transfusion, acute chest syndrome, priapism requiring facility visit (sVOE), hepatic sequestration, or splenic sequestration; confirmatory genetic testing; failure or intolerance to hydroxyurea at any point; clinically fit and stable for transplantation (documented evaluation required); treatment must be performed at an Authorized Treatment Center; prescriber must confirm FDA label parameters, screening and monitoringsee node text

    The CASGEVY™ indication for transfusion-dependent beta-thalassemia (TDT) is not part of the CGT Model and is excluded from coverage under this policy. CASGEVY coverage within the CGT Model applies only to its sickle cell disease indication and to members meeting the MDH clinical criteria adopted by PPMCO (see therapy‑specific criteria).

    All requests for gene therapy require prior authorization and will be reviewed by plan Medical Directors using Maryland Medicaid clinical criteria. Requests that do not meet MDH clinical criteria as applied in prior authorization review are subject to denial. Denials may be appealed through Johns Hopkins Health Plans appeal and state fair hearing processes, and MDH retains discretion to review preauthorization denials for appropriateness and alignment with Model clinical criteria.

    Billing and Coding for Gene Therapies

    CASGEVYHCPCS
    J3392Injection, exagamglogene autotemcel, per treatment
    LYFGENIAHCPCS
    J3394Injection, lovotibeglogene autotemcel, per treatment
    inv-06: CASGEVY recurrent VOCs — criterion summary
    CriterionRecurrent vaso-occlusive crises (VOCs) defined as >= 2 documented VOCs per year in the previous 24 months (provider attestation accepted).
    Age requirementFor use in patients ages 12 years and older.
    Prescriber requirementPrescribed by or in collaboration with a Board Certified Hematologist with SCD expertise.
    Additional clinical requirementsConfirmatory genetic testing; prior use or intolerance of hydroxyurea at any point; patient clinically fit and stable for transplantation.
    inv-07: LYFGENIA VOE frequency — criterion summary
    Criterion

    Provider Requirements and Prior Authorization

    Prior Authorization

    Prior authorization required for CGT Model therapies

    Prior authorization is required for all requests for CASGEVY (J3392) and LYFGENIA (J3394) under the CGT Model; requests will be reviewed by plan Medical Directors using Maryland Medicaid clinical criteria.

    • Codes: J3392 (CASGEVY), J3394 (LYFGENIA).
    • Authorizations are valid for at least 12 months from the decision date.
    Step Therapy

    No step therapy required

    Johns Hopkins Health Plans will not impose step therapy prior to accessing the covered gene therapies under the CGT Model.

    Background and Policy Context

    The CMS Cell and Gene Therapy Access Model establishes a multi-state approach and uses outcomes‑based agreements to improve Medicaid beneficiary access to gene therapies for sickle cell disease. Under the Model in Maryland, two gene therapies (CASGEVY and LYFGENIA) are covered when MDH clinical criteria are met, treatment is delivered at an Authorized Treatment Center, and required clinical documentation and monitoring are provided over the post‑treatment care journey.

    Definitions and Care Journey

    inv-13: Care journey for CGT Model participants
    Preparation and disease managementInitial preparation including ongoing disease management before stem cell collection.
    Stem cell collection (apheresis)Collection of the patient’s stem cells via apheresis for gene therapy manufacture.
    Manufacture of gene therapyCreation/manufacture of the gene therapy product using the patient’s stem cells prior to infusion.
    Infusion and recoveryInfusion of the gene therapy product followed by immediate recovery period and monitoring.
    Structured follow-up schedulePost-infusion follow-up with an initial 6-week visit, then monthly visits for the first year, transitioning to annual visits thereafter.
    Policy Summary
    PayerJohns Hopkins Health Plans
    PolicyCell and Gene Therapy Access Model - PPMCO
    Policy CodePolicy CMS24.26
    Change TypeAdded authorized treatment center
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with a letter of medical necessity and supporting clinical documentation demonstrating MDH clinical criteria; requests will be reviewed by plan Medical Directors.
    SourceLink
    On This Page
    Coverage Criteria for CGT Model TherapiesBilling and Coding for Gene TherapiesProvider Requirements and Prior AuthorizationBackground and Policy ContextDefinitions and Care Journey
    Experienced >= 4 vaso-occlusive episodes (VOEs) in the previous 24 months OR currently receiving chronic transfusion therapy for recurrent VOEs.
    Age requirementFor use in patients 12 years of age and older at the expected time of gene therapy administration.
    Prescriber requirementPrescribed by or in collaboration with a Board Certified Hematologist with SCD expertise; treatment performed in an Authorized Treatment Center.
    Additional clinical requirementsConfirmatory genetic testing; failure or intolerance to hydroxyurea at any point; patient clinically fit and stable for transplantation.
    Documentation Required

    Required documentation for prior authorization

    Submit a letter of medical necessity and supporting clinical documentation (e.g., evaluations) no greater than 6 months old; documentation must demonstrate the applicable MDH clinical criteria.

    • Include confirmatory genetic testing and evidence of transplant fitness where required by MDH criteria.
    • Provide documentation of prior hydroxyurea use or intolerance when applicable.
    Denial Risk

    Prior authorization and denial review process

    All requests for gene therapy require prior authorization and will be reviewed by plan Medical Directors using Maryland Medicaid clinical criteria; denials may be reviewed by MDH for appropriateness and alignment with Model criteria.

    • Requests that do not meet MDH clinical criteria (as reviewed by plan Medical Directors) are subject to denial.
    • Members may appeal denials through JHHP appeal and state fair hearing processes; MDH may review preauthorization denials.